{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:03:27Z","timestamp":1790370207490,"version":"4.1.0"},"reference-count":6,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008844","name":"Liaoning University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymgme.2026.110224","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:37:32Z","timestamp":1784936252000},"page":"110224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disease duration and phenotypic heterogeneity in late-onset Pompe disease: Implications for individualized therapy"],"prefix":"10.1016","volume":"149","author":[{"given":"ShiHeng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DanJun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ymgme.2026.110224_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2026.109874","article-title":"Alglucosidase alfa demonstrates effectiveness and safety in Chinese patients with late-onset Pompe disease: a multi-center prospective study","volume":"148","author":"Li","year":"2026","journal-title":"Mol. Genet. Metab."},{"issue":"8","key":"10.1016\/j.ymgme.2026.110224_bb0010","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1007\/s00415-024-12489-9","article-title":"Changes in forced vital capacity over\u226413 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe registry","volume":"271","author":"Berger","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2026.110224_bb0015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-7-88","article-title":"Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study","volume":"7","author":"van der Beek","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2026.110224_bb0020","doi-asserted-by":"crossref","first-page":"107715","DOI":"10.1016\/j.ymgme.2023.107715","article-title":"Variant classification for Pompe disease; ACMG\/AMP specifications from the ClinGen lysosomal diseases variant curation expert panel","volume":"140","author":"Goldstein","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110224_bb0025","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41392-024-01770-y","article-title":"Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.ymgme.2026.110224_bb0030","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671922600507X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671922600507X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:39:55Z","timestamp":1790368795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109671922600507X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":6,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S109671922600507X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110224","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease duration and phenotypic heterogeneity in late-onset Pompe disease: Implications for individualized therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110224","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110224"}}